Aditxt Inc Stock Price, News & Analysis

Aditxt, Inc. (NASDAQ: ADTX) has amended its agreement with AiPharma Global, extending the deadline for a definitive agreement from November 30, 2021, to December 16, 2021. The amendment also eliminates a $4 million termination fee and reduces AiPharma's borrowing capacity from $8.5 million to $8 million. A cash payment of $500,000 will be required at closing. CEO Amro Albanna expressed optimism about aligning opportunities with AiPharma for 2022, but noted that the agreement remains subject to due diligence and various approvals.

Aditxt, Inc. (NASDAQ: ADTX) has announced a public offering of 16,575,000 units, priced at $1.05 each, to raise approximately $17.4 million. The units consist of shares of common stock and warrants for additional shares at an exercise price of $1.15, expiring in five years. The underwriter, Dawson James Securities, has a 45-day option to purchase up to 2,486,250 additional units. This offering follows a previously filed shelf registration statement with the SEC. Closing is expected on December 3, 2021, pending customary conditions.

Aditxt, Inc. (NASDAQ: ADTX) has announced an underwritten public offering of common stock and warrants. Dawson James Securities, Inc. will serve as the sole book-running manager for this offering. The offering is made under an effective shelf registration statement filed with the SEC. A prospectus supplement will be filed with the SEC and available online. Aditxt focuses on technologies aimed at enhancing immune system health through monitoring and reprogramming.

Aditxt, Inc. (NASDAQ: ADTX) has introduced AditxtScore™ for assessing COVID-19 immune status, marking its deployment by the Johnson County Sheriff's Office, Kansas' largest law enforcement agency. This platform provides a personalized immune profile, quantifying individuals' immune responses to COVID-19 with precision. It helps guide vaccination decisions based on antibody levels. Company officials, including Co-founder Amro Albanna, highlight the significance of tailored immune monitoring for effective health management amidst the pandemic.

Aditxt, Inc. (NASDAQ: ADTX) announced a webinar scheduled for 2 PM ET today to discuss its recent announcements. CEO Amro Albanna will provide comprehensive information to both current and prospective investors. Participants can submit questions via email at aditxt@edisongroup.com. To join the webinar, attendees can click here or enter the link in their browser.

Aditxt, Inc. (NASDAQ: ADTX) announced that the Phase 3 PRESECO trial of Avigan®/Reeqonus™ for COVID-19 did not meet its primary endpoint of time to sustained clinical recovery. Ongoing data analysis is expected. Additionally, Aditxt is in the process of acquiring a subsidiary of AiPharma Global, which holds rights to the antiviral favipiravir. This acquisition aims to enhance Aditxt's portfolio in antiviral therapies to address infectious diseases. CEO Amro Albanna emphasized the importance of evaluating the trial outcomes in conjunction with AiPharma Global.

Aditxt, Inc. (NASDAQ: ADTX) has partnered with CLX Health to enhance the global rollout of AditxtScore™ for COVID-19. This collaboration aims to expand sample collection sites through the TrustAssure network, which offers access to over 5,000 locations in the U.S. and 15,000 worldwide across 81 countries. AditxtScore™ provides individuals with a comprehensive immune profile, critical for travelers managing their health risks. This partnership is viewed as a strategic move to increase brand recognition for AditxtScore™ and improve public health responses during the COVID-19 pandemic.

Aditxt, Inc. has successfully closed its underwritten public offering of 2,833,333 common stock shares, priced at $1.50 per share, yielding gross proceeds of $4.25 million. The net proceeds, approximately $3.91 million after discounts, will partially fund obligations under a prior agreement with AiPharma Global Holdings made on October 4, 2021. The offering is executed under a shelf registration declared effective by the SEC on July 13, 2021. Aditxt focuses on innovations to enhance immune health through monitoring and reprogramming technologies.

Aditxt, a biotech innovation company focused on immune system health, announced that CEO Amro Albanna will present at the Dawson James Small Cap Growth Conference on October 21, 2021, at 2:50 p.m. ET in Jupiter, Florida. The conference aims to gather senior executives from approximately 40 small-cap growth companies in healthcare, technology, and consumer sectors, facilitating connections with institutional funds and high-net-worth investors. Aditxt specializes in immune monitoring and reprogramming technologies currently in pre-clinical development.